David P. Luci

Insider Reports History

Latest reporting-owner signature: /s/ Kostantinos Skordalos, Power of Attorney for: David P. Luci
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for David P. Luci

Form 4 holding President and CEO, Director

Acurx Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 1,097,458
Estimated value: $1,113,920
Report date: 06 Jan 2025
Price: $1.02
Ownership: Direct

Form 4 holding President and CEO, Director

Acurx Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 35,000
Estimated value: $35,525
Report date: 06 Jan 2025
Price: $1.02
Ownership: By child

Form 4 holding President and CEO, Director

Acurx Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 15,083
Estimated value: $15,309
Report date: 06 Jan 2025
Price: $1.02
Ownership: By spouse

Form 4 holding President and CEO, Director

Acurx Pharmaceuticals, Inc.

Security class: Stock Option
Shares / value: 250,000
Estimated value
Report date: 23 Feb 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding President and CEO, Director

Acurx Pharmaceuticals, Inc.

Security class: Warrants for Common Stock
Shares / value: 49,261
Estimated value
Report date: 06 Jan 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding President and CEO, Director

Acurx Pharmaceuticals, Inc.

Security class: Stock Option
Shares / value: 37,100
Estimated value
Report date: 20 Apr 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by David P. Luci

4 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 20 Apr 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Apr 2026, 16:17
Role: President and CEO, Director
Next action: Open filing details

4 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 05 Feb 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 06 Feb 2025, 17:46
Role: President and CEO, Director, 10%+ Owner
Next action: Open filing details

4 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 06 Jan 2025
Transactions: 2
Transaction value: +$50,000
Accepted by SEC: 08 Jan 2025, 16:31
Role: President and CEO, Director, 10%+ Owner
Next action: Open filing details

4 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 23 Feb 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Apr 2024, 21:56
Role: President and CEO, Director, 10%+ Owner
Next action: Open filing details

4 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 03 Jan 2024
Transactions: 2
Transaction value: +$70,066
Accepted by SEC: 04 Jan 2024, 16:24
Role: President and CEO, Director, 10%+ Owner
Next action: Open filing details

4 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 13 Feb 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 24 Feb 2023, 15:31
Role: President and CEO, Director, 10%+ Owner
Next action: Open filing details

4 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 27 Jul 2022
Transactions: 3
Transaction value: +$75,001
Accepted by SEC: 29 Jul 2022, 17:01
Role: President and CEO, Director, 10%+ Owner
Next action: Open filing details

4 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 19 Nov 2021
Transactions: 1
Transaction value: +$24,960
Accepted by SEC: 22 Nov 2021, 15:05
Role: President and CEO, Director, 10%+ Owner
Next action: Open filing details

4 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 29 Jun 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 06 Jul 2021, 16:06
Role: President and CEO, Director, 10%+ Owner
Next action: Open filing details

3 ACXP

Acurx Pharmaceuticals, Inc.

Report period: 24 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 24 Jun 2021, 18:23
Role: President and CEO, Director, 10%+ Owner
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .